A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Decision date
06/05/2026
Enrollment target
30
Sites
Netherlands
Condition studied
Autosomal Dominant Polycystic Kidney Disease
Eligibility
Age group
18-64 years
Sex
Female, Male
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.